Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl) arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: Potential substance abuse therapeutic agents

Journal of Medicinal Chemistry

Volumn 50, Issue 17, 2007, Pages 4135-4146

  Grundt, Peter ^a   Prevatt, Katherine M ^a   Cao, Jianjing ^a   Taylor, Michelle ^b   Floresca, Christina Z ^b   Choi, Ji Kyung ^c   Jenkins, Bruce G ^c   Luedtke, Robert R ^b   Newman, Amy Hauck ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 FLUORENYLAMIDE; 2 PYRIDYLPHENYLAMIDE; ACETIC ACID DERIVATIVE; AMIDE; BENZENE DERIVATIVE; BUTYLAMIDE; CHLORINE DERIVATIVE; CJB 090; COCAINE; CYCLOPROPANE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE 4 RECEPTOR; HYDROXYL GROUP; JJC 2 071; LIGAND; N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUT 2 ENYL] 4 PYRIDIN 2 YLBENZAMIDE; NGB 2904; PARTIAL AGONIST; PG 01037; PIPERAZINE DERIVATIVE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; QUINPIROLE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CHEMICAL MODIFICATION; DRUG DEPENDENCE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIPOPHILICITY; MITOGENESIS; NONHUMAN; RECEPTOR OCCUPANCY; STRUCTURE ACTIVITY RELATION; SUBSTANCE ABUSE;

AMIDES; ANIMALS; BENZAMIDES; BINDING, COMPETITIVE; BRAIN; CELL LINE; HUMANS; LIGANDS; MAGNETIC RESONANCE IMAGING; MITOSIS; PIPERAZINES; PYRIDINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, DOPAMINE D3; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTANCE-RELATED DISORDERS;

EID: 34548138905     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0704200     Document Type: Article

References (45)

1. Wise, R. A. D-1-type and D-2-type contributions to psychomotor sensitization and reward. Implications for pharmacological treatment strategies. Clin. Neuropharmacol. 1995, 18, S74-S83.
2. Volkow, N. D.; Wang, G. J.; Fowler, J. S.; Logan, J.; Gatley, S. J.; Wong, C.; Hitzemann, R.; Pappas, N. R. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D-2 receptors. J. Pharmacol. Exp. Ther. 1999, 291, 409-415.
3. Volkow, N. D.; Fowler, J. S.; Wang, G. J.; Swanson, J. M. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol. Psychiatry 2004, 9, 557-569.
4. Nader, M. A.; Morgan, D.; Gage, H. D.; Nader, S. H.; Calhoun, T. L.; Buchheimer, N.; Ehrenkaufer, R.; Mach, R. H. PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat. Neurosci. 2006, 9, 1050-1056.
5. Narendran, R.; Slifstein, M.; Hwang, D. R.; Hwang, Y. Y.; Scher, E.; Reeder, S.; Martinez, D.; Laruelle, M., Amphetamine-induced dopamine release: duration of action as assessed with the D-2/3 receptor agonist radiotracer (-)-N-[C-11]propyl-norapomorphine ([C-11]NPA) in an anesthetized nonhuman primate. Synapse 2007, 61, 106-109.
6. Heidbreder, C. A.; Andreoli, M.; Marcon, C.; Thanos, P. K.; Ashby, C. R.; Gardner, E. L. Role of dopamine D-3 receptors in the addictive properties of ethanol. Drugs Today 2004, 40, 355-365.
7. Newman, A. H.; Grundt, P.; Nader, M. A. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J. Med. Chem. 2005, 48, 3663-3679.
8. Joyce, J. N.; Milian, M. J. Dopamine D-3 receptor antagonists as therapeutic agents. Drug Discovery Today 2005, 10, 917-925.
9. Le Foll, B.; Goldberg, S. R.; Sokoloff, P. The dopamine D-3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology 2005, 49, 525-541.
10. Luedtke, R. R.; Mach, R. H. Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders. Curr. Pharm. Des. 2003, 9, 643-671.
11. Boeckler, F.; Gmeiner, P. The structural evolution of dopamine D-3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects. Pharmacol. Ther. 2006, 112, 281-333.
12. Zhang, A.; Neumeyer, J. L.; Baldessarini, R. J. Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders. Chem. Rev. 2007, 107, 274-302.
13. Sokoloff, P.; Giros, B.; Martres, M. P.; Bouthenet, M. L.; Schwartz, J. C. Molecular-cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990, 347, 146-151.
14. Levant, B. The D-3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol. Rev. 1997, 49, 231-252.
15. Grundt, P.; Carlson, E. E.; Cao, J. J.; Bennett, C. J.; McElveen, E.; Taylor, M.; Luedtke, R. R.; Newman, A. H. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]-butyl} arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J. Med. Chem. 2005, 48, 839-848.
16. Leopoldo, M.; Lacivita, E.; Colabufo, N. A.; Berardi, F.; Perrone, R. Synthesis and binding profile of constrained analogues of N-[4-(4- arylpiperazin-1-yl)butyl]-3-methoxybenzamides, a class of potent dopamine D-3 receptor ligands. J. Pharm. Pharmacol. 2006, 58, 209-218.
17. Robarge, M. J.; Husbands, S. M.; Kieltyka, A.; Brodbeck, R.; Thurkauf, A.; Newman, A. H. Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl] alkylfluorenylcarboxamides as novel ligands selective for the dopamine D-3 receptor subtype. J. Med. Chem. 2001, 44, 3175-3186.
18. Bettinetti, L.; Schlotter, K.; Hubner, H.; Gmeiner, P. Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists. J. Med. Chem. 2002, 45, 4594-4597.
19. Geneste, H.; Backfisch, G.; Braje, W.; Delzer, J.; Haupt, A.; Hutchins, C. W.; King, L. L.; Lubisch, W.; Steiner, G.; Teschendorf, H. J.; Unger, L.; Wernet, W. Synthesis and SAR of highly potent and selective dopamine D-3-receptor antagonists: Quinolin(di)one and benzazepin(di)one derivatives. Bioorg. Med. Chem. Lett. 2006, 16, 658-662.
20. Collins, G. T.; Witkin, J. M.; Newman, A. H.; Svensson, K. A.; Grundt, P.; Cao, J. J.; Woods, J. H., Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J. Pharmacol. Exp. Ther. 2005, 314, 310-319.
21. Martelle, J. L.; Claytor, R.; Ross, J. T.; Reboussin, B. A.; Newman, A. H.; Nader, M. A., Effects of two novel D3-selective compounds, NGB2904 and CJB090, the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J. Pharmacol. Exp. Ther. 2007, 321, 573-582.
22. Gilbert, J. G.; Newman, A. H.; Gardner, E. L.; Ashby, C. R.; Heidbreder, C. A.; Pak, A. C.; Peng, X. Q.; Xi, Z. X. Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D-3 receptors. Synapse 2005, 57, 17-28.
23. Spealman, R. D.; Piatt, D. M. Personal communication.
24. Choi, J. K.; Chen, Y. I.; Hamel, E.; Jenkins, B. G. Brain hemodynamic changes mediated by dopamine receptors: Role of the cerebral microvasculature in dopamine-mediated neurovascular coupling. Neuroimage 2006, 30, 700-712.
25. Chen, Y. C. I.; Choi, J. K.; Andersen, S. L.; Rosen, B. R.; Jenkins, B. G. Mapping dopamine D2/D3 receptor function using pharmacological magnetic resonance imaging. Psychopharmacology 2005, 180, 705-715.
26. Schwarz, A.; Gozzi, A.; Reese, T.; Bertani, S.; Crestan, V.; Hagan, J.; Heidbreder, C.; Bifone, A. Selective dopamine D-3 receptor antagonist SB-277011-A potentiates phMRI response to acute amphetamine challenge in the rat brain. Synapse 2004, 54, 1-10.
27. Richtand, N. M.; Kelsoe, J. R.; Segal, D. S.; Kuczenski, R. Regional quantification of D1, D2, and D3 dopamine-receptor messenger-RNA in rat-brain using a ribonuclease protection assay. Mol. Brain Res. 1995, 33, 97-103.
28. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44, 235-249.
29. Yuan, J.; Chen, X.; Brodbeck, R.; Primus, R.; Braun, J.; Wasley, J. W. F.; Thurkauf, A. NGB 2904 and NGB 2849: two highly selective dopamine D-3 receptor antagonists. Bioorg. Med. Chem. Lett. 1998, 8, 2715-2718.
30. Cruickshank, P. A.; Fishman, M. Studies in alkylation. 2. Reactions of epoxyalkyl bromides. J. Org. Chem. 1969, 34, 4060-4065.
31. Gong, Y.; Pauls, H. W. A convenient synthesis of heteroaryl benzoic acids via Suzuki reaction. Synlett 2000, 829-831.
32. Hackling, A.; Ghosh, R.; Perachon, S.; Mann, A.; Holtje, H. D.; Wermuth, C. G.; Schwartz, J. C.; Sippl, W.; Sokoloff, P.; Stark, H. N-(omega-(4- (2-Methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D-2 and D-3 receptor ligands. J. Med. Chem. 2003, 46, 3883-3899.
33. Newman, A. H.; Cao, J. J.; Bennett, C. J.; Robarge, M. J.; Freeeman, R. A.; Luedtke, R. R., N-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]-butyl, butenyl and butynyl}arylcarboxamides as novel dopamine D-3 receptor antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 2179-2183.
34. Ashton, W. T.; Meurer, L. C.; Cantone, C. L.; Field, A. K.; Hannah, J.; Karkas, J. D.; Liou, R.; Patel, G. F.; Perry, H. C.; Wagner, A. F.; Walton, E.; Tolman, R. L. Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2- (hydroxymethyl)cyclopropyl]methyl]guanine and related-compounds. J. Med. Chem. 1988, 31, 2304-2315.
35. Luedtke, R. R.; Freeman, R. A.; Boundy, V. A.; Martin, M. V.; Huang, Y. S.; Mach, R. H. Characterization of I-125-IABN, a novel azabicyclononane benzamide selective for D2-like dopamine receptors. Synapse 2000, 38, 438-449.
36. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 2000, 43, 3714-3717.
37. ChemDraw Ultra 9.0; CambridgeSoft: Cambridge, MA, 2004.
38. Chu, W. H.; Tu, Z.; McElveen, E.; Xu, J. B.; Taylor, M.; Luedtke, R. R.; Mach, R. H. Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D-3 receptor ligands. Bioorg. Med. Chem. 2005, 13, 77-87.
39. Leopoldo, M.; Lacivita, E.; De Giorgio, P.; Colabufo, N. A.; Niso, M.; Berardi, F.; Perrone, R. Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands for visualization of brain dopamine D-3 receptors. J. Med. Chem. 2006, 49, 358-365.
40. Kuhnast, B.; Valette, H.; Besret, L.; Demphel, S.; Coulon, C.; Ottaviani, M.; Guillermier, M.; Bottlaender, M.; Dolle, F. Synthesis and radiolabeling of N-[4-[4-(2-[C-11]methoxyphenyl)piperazin-1-yl]butyl]benzo[b] thiophene-2-carboxamide, a potential radiotracer for D-3 receptor imaging with PET. Nucl. Med. Biol. 2006, 33, 785-795.
41. Salama, I.; Hocke, C.; Utz, W.; Prante, O.; Boeckler, F.; Hubner, H.; Kuwert, T.; Gmeiner, P. Structure-selectivity investigations of D-2-like receptor ligands by CoMFA and CoMSIA guiding the discovery of D-3 selective PET radioligands. J. Med. Chem. 2007, 50, 489-500.
42. Macdonald, G. J.; Branch, C. L.; Hadley, M. S.; Johnson, C. N.; Nash, D. J.; Smith, A. B.; Stemp, G.; Thewlis, K. M.; Vong, A. K. K.; Austin, N. E.; Jeffrey, P.; Winborn, K. Y.; Boyfield, I.; Hagan, J. J.; Middlemiss, D. N.; Reavill, C.; Riley, G. J.; Watson, J. M.; Wood, M.; Parker, S. G.; Ashby, C. R. Design and synthesis of trans- 3-(2-(4-((3-(3-(5-methyl-1,2,4- oxadiazolyl))phenyl)carboxamido)-cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4, 5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D-3 receptor antagonist. J. Med. Chem. 2003, 46, 4952-4964.
43. Leopoldo, M.; Lacivita, E.; Colabufo, N. A.; Contino, M.; Berardi, F.; Perrone, R. First structure-activity relationship study on dopamine D-3 receptor agents with N-[4-(4-arylpiperazin-1-yl)butyl]-arylcarboxamide structure. J. Med. Chem. 2005, 48, 7919-7922.
44. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
45. Toll, L.; Berzetei-Gurske, I. P.; Polgar, W. E.; Brandt, S. R.; Adapa, I. D.; Rodriguez, L.; Schwartz, R. W.; Haggart, D.; Obrien, A.; White, A.; Kennedy, J. M.; Craymar, K.; Farrington, L.; Auh, J. S. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res. Monogr. 1998, 178, 440-466.